A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
A study for patients with Idiopathic Parkinson's Disease using study drug CVT-301
Sponsor: Acorda Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAO4151
U.S. Govt. ID: NCT02240030
Contact: Amber Servi: 212-305-3665 / ads2178@columbia.edu
Additional Study Information: The purpose of this research is to find out whether an investigational drug called CVT-301, is helpful to people with Parkinson's Disease (PD). The treatment involves a new method for taking levodopa (LD) through an inhaler (which is like an asthma inhaler) to provide relief of motor fluctuations (OFF episodes), which are experienced by many Parkinson's disease patients.
This study is closed
Investigator
Cheryl Waters, MD
Do You Qualify?
Have you been diagnosed with Idiopathic Parkinson's Disease (PD)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Amber Servi
ads2178@columbia.edu
212-305-3665
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE